Drugs / VRVg-2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03145766 | Apr 2017 → Jan 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 34 trials · 2 met primary | ||||||
| Phase 3 | NCT04594551 | Oct 2020 → Jun 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04478084 | Aug 2020 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04127786 | Oct 2019 → Mar 2020 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT03965962 | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRVg-2 | “Group 1: VRVg-2 + HRIG” NCT04594551 ↗ |
| Modality | Vaccine | “Purified vero rabies vaccine - serum free VRVg-2” NCT04478084 ↗ |
| Route | Intramuscular | “VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28.” NCT03145766 ↗ |